HC Wainwright Lowers LifeMD (NASDAQ:LFMD) Price Target to $13.00

Key Points

• HC Wainwright has lowered the price target for LifeMD (NASDAQ:LFMD) from $14.00 to $13.00, while maintaining a "buy" rating, indicating a potential upside of 99.08% from current prices.
• LifeMD's shares are down 44.8% and currently trade at $6.53, with a market capitalization of $296.79 million.
• The company has received mixed ratings from analysts, with five analysts$12.86.

LifeMD (NASDAQ:LFMD - Free Report) had its target price lowered by HC Wainwright from $14.00 to $13.00 in a report published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for LifeMD's Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.09 EPS, Q3 2026 earnings at $0.13 EPS, Q4 2026 earnings at $0.20 EPS and FY2026 earnings at $0.47 EPS.

Several other brokerages have also issued reports on LFMD. Wall Street Zen lowered shares of LifeMD from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Lake Street Capital cut their price objective on shares of LifeMD from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday. KeyCorp reduced their price objective on LifeMD from $14.00 to $12.00 and set an "overweight" rating for the company in a research note on Wednesday. Finally, BTIG Research lifted their target price on LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Wednesday, June 18th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $12.86.

LifeMD Stock Performance

Shares of LFMD traded up $0.21 during trading hours on Thursday, hitting $6.82. The stock had a trading volume of 2,887,298 shares, compared to its average volume of 2,214,485. LifeMD has a 12 month low of $3.99 and a 12 month high of $15.84. The stock has a fifty day moving average price of $11.86 and a 200 day moving average price of $8.47. The company has a debt-to-equity ratio of 9.21, a current ratio of 0.77 and a quick ratio of 0.77. The firm has a market capitalization of $323.40 million, a PE ratio of -32.48 and a beta of 1.72.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.05. The firm had revenue of $65.70 million for the quarter, compared to the consensus estimate of $62.47 million. Analysts anticipate that LifeMD will post -0.56 EPS for the current year.

Insider Activity

In other news, insider Eric Harold Yecies sold 15,000 shares of the firm's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $12.25, for a total transaction of $183,750.00. Following the sale, the insider directly owned 16,100 shares in the company, valued at $197,225. This trade represents a 48.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Stefan Galluppi sold 85,000 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $12.38, for a total transaction of $1,052,300.00. Following the completion of the transaction, the insider directly owned 80,449 shares of the company's stock, valued at $995,958.62. This represents a 51.38% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 275,000 shares of company stock valued at $3,564,550. 18.40% of the stock is currently owned by company insiders.

Institutional Trading of LifeMD

Institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC purchased a new position in LifeMD in the 1st quarter worth approximately $35,000. CWM LLC lifted its holdings in shares of LifeMD by 17.5% in the first quarter. CWM LLC now owns 9,050 shares of the company's stock worth $49,000 after buying an additional 1,351 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of LifeMD by 148.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company's stock worth $50,000 after buying an additional 2,185 shares in the last quarter. ProShare Advisors LLC bought a new position in shares of LifeMD during the fourth quarter worth $51,000. Finally, Oxford Asset Management LLP bought a new stake in LifeMD in the 4th quarter valued at $52,000. Hedge funds and other institutional investors own 35.52% of the company's stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.